International Stem Cell Corp. (ISCO) Operating Subsidiary Signs Distribution Agreement

International Stem Cell Corp. announced today that Lifeline Skin Care, its operating subsidiary, has signed a distribution agreement with Grupo Venta Internacional, S.A de C. V., Mexico’s largest distributor of aesthetic and reconstructive products. Grupo Venta Internacional will offer Lifeline’s breakthrough stem cell skin care products to health care professionals throughout Mexico, the second largest market for aesthetic skin care in Central and South America. The agreement is effective immediately. ISCO is a California-based biotechnology company developing novel stem cell-based therapies and biomedical products.

As reported by Euromonitor International, the Mexican skin care market is expected to be worth approximately $2 billion in 2014, citing anti-aging products as being among the most popular. With 24 years’ experience in the plastic surgery and dermatology market in Mexico, and the credibility and presence of their 85-person national sales force, Grupo Venta Internacional (GVI) is well qualified to help Lifeline become very successful in this growing market.

President of GVI, Gabriela Gonzalez Alonso commented, “Plastic surgeons and dermatologists in Mexico are very excited about the potential for stem cell skin care products. They’re already familiar with the benefits of growth factors for skin rejuvenation, but the concept of stem cells elevates the technology to a whole new level. A brand that is backed by a biotech company adds even more credibility.”

“Expanding international sales is a key part of our growth strategy,” said Donna Queen, President of Lifeline Skin Care. “Initially Lifeline will be marketed only to physicians, which will lend credibility to the brand. The recommendation of a trusted health care professional is consistently rated as one of the most important consideration when selecting anti-aging skincare products. For this reason we’re especially pleased to be working with Grupo Venta Internacional.”

Lifeline Skin Care works on developing, marketing, and selling advanced anti-aging skin care products based on technology patented by ISCO. The technology uses ingredients that have been extracted from ISCO’s human, parthenogenetic stem cells and are known to reduce the visible signs of skin aging. Over the last 18 months, Lifeline’s sales have grown on average by over 40% a quarter, on a year to year basis. Lifeline Skin Care is available from dermatologists, plastic surgeons, selected medical spas, and day spas.

International Stem Cell Corporation works on the therapeutic applications of human parthenogenetic stem cells (hpSCs) and the development and commercialization of cell-based research and cosmetic products. ISCO’s core technology, parthenogenesis, creates pluripotent human stem cells from unfertilized oocytes (eggs) and in so doing avoids ethical issues commonly associated with the use or destruction of viable human embryos. ISCO scientists have created the first parthenogenetic, homozygous stem cell line that can be a source of therapeutic cells for hundreds of millions of people of different genders, ages, and races with minimal immune rejection after transplantation. hpSCs offer the potential to create the first true stem cell bank, UniStemCell™.

For more information, visit www.internationalstemcell.com

About QualityStocks

QualityStocks is committed to connecting subscribers with companies that have huge potential to succeed in the short and long-term future. We offer several ways for investors to find, evaluate, and learn more about investing in these companies.

Sign up for “The QualityStocks Daily Newsletter” at www.QualityStocks.net

The Quality Stocks Daily Blog http://blog.qualitystocks.net

The Quality Stocks Daily Videos http://videocharts.qualitystocks.net

 The Quality Stocks “Ones to Watch” http://gotstocks.qualitystocks.net

Please see disclaimer on the QualityStocks website: http://disclaimer.qualitystocks.net